Page 840 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

818 Index

Choroidal melanomas, 680 Class D cyclin, 36–37 Communication
Chromaffin cells, 573 CLDC. see Cationic lipid-DNA complex approaches to, 316–319
Clinical-pathologic correlation, 74–75
compassion fatigue, 318–319
Chromatin
VetBooks.ir interphase and, 36 Clinical relevance, interpretation of, 86t delivering bad news, 316
stippled pattern of, 131
euthanasia discussions and, 318
Clinical Review Board, function of, 348
view of, 131f Clinical target volume (CTV), 215–216 grief and loss, 318
Chromosomal abnormality, 146 Clinical trial, 340–351 palliative care transition, 317
Chromosomal banding, 147 drug development and, 340–346 prognosis discussion, 316–317
Chromosomal breakpoint, 42 phase 0, 343 qualify of life assessment, 317
Chromosomal fragile site expression, 382–383 phase I, 340–342 client expectations and, 311
Chromosomal instability, 46–47, 47f phase II, 342–343 paternalism and, 311
Chromosomal translocation, 40f, 42 phase III, 343–344 relationship-centered approach to, 310–311
Chromosome phase IV, 344–346 skills for, 313–316
metaphase and, 36 phases and goals of, 341t building relationships, 314–315
metaphase preparations from, 147 effectiveness versus efficacy, 344–345 explaining and complaining, 314
prophase and, 36 errors in, 343 gathering information, 313–314
replication of, 47f ethical standards in, 348 providing structure, 315–316
Chromosome 9, 11–12, 148 Food and Drug Administration and, 345 Community member, 344
Chromosome 22, 11–12, 148 frequentist approach in, 346–347 Comparative genomic hybridization (CGH)
Chromosome 26, 11–12 good manufacturing/clinical practice chromosome number and, 147
Chromosome number criteria for, 344 T-cell lymphoma and, 147
abnormality in, 147 informed consent for, 348 Comparative Ocular Pathology Laboratory of
comparative genomic hybridization and, elements of, 348b Wisconsin (COPLOW), 675, 676f
147 masitinib for mast cell tumors, 393 Comparative Oncology Trials Consortium
Chromosome-specific paint, 147 power in, 343–344 (COTC), 345
Chronic kidney disease (CKD), in regulatory oversight in, 345 Compassion fatigue, 318–319
cats, 580 regulatory safeguards for, 348 Complementary DNA (cDNA), 151
Chronic lymphocytic leukemia (CLL), small sample size and errors in, 343–344 Compliance, 82t
cell lymphoma versus, 146 veterinary registration trials for, 345 Compton effect, 209
Chronic myelogenous leukemia (CML), Clinician Computed tomography (CT)
10–11 evidence-based medicine and, 81 for adrenal gland neoplasia, 572
abl tyrosine and, 148 neoplasia pathology knowledge by, 75 for adrenal medullary tumors, 573
cancer progenitor and, 10–11 responsibility of, 62 for adrenal tumors, 574
oncogenic mutations in, 347 CLL. see Chronic lymphocytic leukemia advances in, 115
Chronic pain Clonal evolution theory, 9–10 of ground-glass nodule, 117f
analgesics for, 292t Clonality assay, 148 for hyperadrenocorticism, 566
management of, 286 assessment of, 151 of interventional oncology, 174
Chylothorax, 145f for leukemia/lymphoma, 148–151 of maxillary oral melanoma, 375f
CIP/KIP family, 37 Clonogenicity, 50 of pulmonary mass, 118f
Circulating endothelial cell (CEC), biomarker CMC. see Chemistry, manufacturing, and radiation therapy and, 216, 217f
analysis for, 268 control radiography versus, 113
Circulating endothelial progenitor cell CML. see Chronic myelogenous leukemia skull tumor, 3D-reconstructed image of,
(CEP) Coax feeding, 304 116f
biomarker analysis for, 268 Codeine, 292t thyroid carcinoma, 3D-reconstructed image
tumor angiogenesis and, 263 Codman triangle, 528–529 of, 117f
Circulating epithelial cell, survival of, 53 Coherence, 82t for thyroid gland neoplasia, in dogs, 576
Circulating tumor cell Coley, William, 236 use of, 115
arrest of, 54 “Coley’s toxins”, 236 Conditionally replicating adenovirus, 254f
high numbers of, 55 Collaborative relationship, 311 Conditionally replicating virus, 256
Circumanal tumor, 134 Collagen Conjugated monoclonal antibodies, 241
Circumscribed, nevus-like pigmented iridal composition of, 130 Conjunctival tumor, 675–678
growths, 679 view of, 131f clinical signs of, 676–677
Cisplatin, 196–197 Collagenous nevus diagnostic techniques and workup, 677
for canine osteosarcoma, 543t sites for, 104 history of, 676–677
for canine testicular tumors, 630 view of, 105f incidence of, 675, 676f–677f
clinical use of, 196 Collective invasion, 52 natural behavior of, 675–676
for oral melanoma, 375 Colonoscopy, for intestinal tumors, pathology of, 675–676
pharmacology of, 196 464–465 prognosis for, 677–678
CKD. see Chronic kidney disease Colorado State University Flint Animal risk factors for, 675
C-kit gene, 146 Cancer Center, 330 therapy for, 677–678
internal tandem duplication in, 148 Combination analgesics, 295 Connexin, 628
mutation detection by PCR, 149f Combination chemotherapy, 186 Conn’s syndrome, 573